Campbell & Co Investment Adviser’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-15,836
| Closed | -$1.82M | – | 1258 |
|
|
2024
Q3 | $1.82M | Buy |
15,836
+11,055
| +231% | +$1.27M | 0.14% | 217 |
|
|
2024
Q2 | $658K | Buy |
+4,781
| New | +$658K | 0.06% | 539 |
|
|
2024
Q1 | – | Sell |
-2,239
| Closed | -$295K | – | 1285 |
|
|
2023
Q4 | $295K | Buy |
+2,239
| New | +$295K | 0.03% | 925 |
|
|
2023
Q2 | – | Sell |
-9,963
| Closed | -$1.01M | – | 1043 |
|
|
2023
Q1 | $1.01M | Buy |
9,963
+5,869
| +143% | +$594K | 0.19% | 158 |
|
|
2022
Q4 | $489K | Sell |
4,094
-1,884
| -32% | -$225K | 0.12% | 328 |
|
|
2022
Q3 | $635K | Buy |
+5,978
| New | +$635K | 0.14% | 243 |
|
|
2020
Q4 | – | Sell |
-8,029
| Closed | -$772K | – | 523 |
|
|
2020
Q3 | $772K | Buy |
+8,029
| New | +$772K | 0.58% | 20 |
|
|
2020
Q1 | – | Sell |
-23,637
| Closed | -$2.54M | – | 340 |
|
|
2019
Q4 | $2.54M | Buy |
+23,637
| New | +$2.54M | 0.78% | 2 |
|
|
2019
Q1 | – | Sell |
-3,115
| Closed | -$246K | – | 575 |
|
|
2018
Q4 | $246K | Buy |
+3,115
| New | +$246K | 0.24% | 219 |
|